Daniela Ruah

Taylor Swift‘s (TS) Eras Tour Is Projected To Become The Highest-Grossing Tour Of All Time, With An Estimated $1 B In Sales. The Tour Features, E.G., Elaborate Staging, And Over 40 Songs. The Top 3 Highest-Grossing Concert Tours Include Elton John ($853 M), Ed Sheeran ($776 M), And U2 ($736 M). Total Spending On TS Tour In 2023 Is ~$5 B.

…

The First Drug Designed To Slow Brain Destruction In Early Stages Alzheimer’s Patients Has Been Developed. The Drug, Lecanemab, Is An Antibody Engineered To Tell The Immune System To Clear Amyloid From The Brain. Many Are Hailing The Drug As Momentous, Even Though The Benefit Is Small, With The Risk Of Brain Swelling And Bleeding.

…

The US FDA Has Approved The First Smartphone App For Delivering Insulin. The App, T:Connect App From Tandem Diabetes Care, Inc, Will Be Paired With The T:Slim X2 Insulin Pump. The App, Which Can Be Used On Both Android And iOS Phones, Will Display, E.G., The Last 24 Hours Of Glucose Trends, Pump Status Changes And Insulin Therapy Data.

…

Researchers Used Chunks Of Tumour From The Brain Of Patients With Glioblastoma To Print A 3-D Model Similar To What They See In The Patients’ MRI Scans. And Then, Pumped The Patients’ Blood Into The 3-D Model With A Compound That Mimics The Brain, To Test The Efficacy Of A Potential Treatment Before Using It On The Real Body. Cool!

C…

The US FDA, Pending The Clinical Benefit Study, Has Conditionally Approved The First New Alzheimer’s Disease Drug, Since A Drug Was Last Approved In Almost 20 Years, In 2003. The Novel Experimental Drug, Known As Aducanumab Or Aduhelm, Is Intended For Patients With Earliest Stage Of Dementia, And To Slow Alzheimer’s Disease Progression.